Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Murphy-Benenato KE"'
Autor:
An D, Schneller JL, Frassetto A, Liang S, Zhu X, Park JS, Theisen M, Hong SJ, Zhou J, Rajendran R, Levy B, Howell R, Besin G, Presnyak V, Sabnis S, Murphy-Benenato KE, Kumarasinghe ES, Salerno T, Mihai C, Lukacs CM, Chandler RJ, Guey LT, Venditti CP, Martini PGV
Publikováno v:
Cell reports [Cell Rep] 2018 Aug 28; Vol. 24 (9), pp. 2520.
Autor:
An D; Moderna Therapeutics, Cambridge, MA 02139, USA., Schneller JL; Organic Acid Research Section, Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, MD 20892, USA., Frassetto A; Moderna Therapeutics, Cambridge, MA 02139, USA., Liang S; Moderna Therapeutics, Cambridge, MA 02139, USA., Zhu X; Moderna Therapeutics, Cambridge, MA 02139, USA., Park JS; Moderna Therapeutics, Cambridge, MA 02139, USA., Theisen M; Moderna Therapeutics, Cambridge, MA 02139, USA., Hong SJ; Moderna Therapeutics, Cambridge, MA 02139, USA., Zhou J; Moderna Therapeutics, Cambridge, MA 02139, USA., Rajendran R; Moderna Therapeutics, Cambridge, MA 02139, USA., Levy B; Moderna Therapeutics, Cambridge, MA 02139, USA., Howell R; Moderna Therapeutics, Cambridge, MA 02139, USA., Besin G; Moderna Therapeutics, Cambridge, MA 02139, USA., Presnyak V; Moderna Therapeutics, Cambridge, MA 02139, USA., Sabnis S; Moderna Therapeutics, Cambridge, MA 02139, USA., Murphy-Benenato KE; Moderna Therapeutics, Cambridge, MA 02139, USA., Kumarasinghe ES; Moderna Therapeutics, Cambridge, MA 02139, USA., Salerno T; Moderna Therapeutics, Cambridge, MA 02139, USA., Mihai C; Moderna Therapeutics, Cambridge, MA 02139, USA., Lukacs CM; Moderna Therapeutics, Cambridge, MA 02139, USA., Chandler RJ; Organic Acid Research Section, Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, MD 20892, USA., Guey LT; Moderna Therapeutics, Cambridge, MA 02139, USA., Venditti CP; Organic Acid Research Section, Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, MD 20892, USA. Electronic address: venditti@mail.nih.gov., Martini PGV; Moderna Therapeutics, Cambridge, MA 02139, USA. Electronic address: paolo.martini@modernatx.com.
Publikováno v:
Cell reports [Cell Rep] 2017 Dec 19; Vol. 21 (12), pp. 3548-3558.
Autor:
Patel S; Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University , Collaborative Life Science Building, 2730 SW Moody Avenue, Portland, Oregon 97201, United States., Ashwanikumar N; Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University , Collaborative Life Science Building, 2730 SW Moody Avenue, Portland, Oregon 97201, United States., Robinson E; Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University , Collaborative Life Science Building, 2730 SW Moody Avenue, Portland, Oregon 97201, United States., DuRoss A; Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University , Collaborative Life Science Building, 2730 SW Moody Avenue, Portland, Oregon 97201, United States., Sun C; Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University , Collaborative Life Science Building, 2730 SW Moody Avenue, Portland, Oregon 97201, United States.; Department of Radiation Medicine, School of Medicine, Oregon Health and Science University , 3181 SW Sam Jackson Park Road, Portland, Oregon 97239, United States., Murphy-Benenato KE; Moderna Therapeutics , 200 Technology Square, Cambridge, Massachusetts 02139, United States., Mihai C; Moderna Therapeutics , 200 Technology Square, Cambridge, Massachusetts 02139, United States., Almarsson Ö; Moderna Therapeutics , 200 Technology Square, Cambridge, Massachusetts 02139, United States., Sahay G; Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University , Collaborative Life Science Building, 2730 SW Moody Avenue, Portland, Oregon 97201, United States.; Department of Biomedical Engineering, Oregon Health and Science University , Collaborative Life Science Building, 2730 SW Moody Avenue, Portland, Oregon 97201, United States.
Publikováno v:
Nano letters [Nano Lett] 2017 Sep 13; Vol. 17 (9), pp. 5711-5718. Date of Electronic Publication: 2017 Aug 24.
Autor:
Kim A; Infection Innovative Medicines, AstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA aryunkimpharmd@gmail.com., Kutschke A; Infection Innovative Medicines, AstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA., Ehmann DE; Infection Innovative Medicines, AstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA., Patey SA; Infection Innovative Medicines, AstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA., Crandon JL; Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA., Gorseth E; Infection Innovative Medicines, AstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA., Miller AA; Infection Innovative Medicines, AstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA., McLaughlin RE; Infection Innovative Medicines, AstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA., Blinn CM; Infection Innovative Medicines, AstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA., Chen A; Infection Innovative Medicines, AstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA., Nayar AS; Infection Innovative Medicines, AstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA., Dangel B; Infection Innovative Medicines, AstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA., Tsai AS; Infection Innovative Medicines, AstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA., Rooney MT; Infection Innovative Medicines, AstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA., Murphy-Benenato KE; Infection Innovative Medicines, AstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA., Eakin AE; Infection Innovative Medicines, AstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA., Nicolau DP; Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.
Publikováno v:
Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2015 Dec; Vol. 59 (12), pp. 7743-52. Date of Electronic Publication: 2015 Oct 05.
Autor:
Murphy-Benenato KE; Infection Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA., Gingipalli L; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA., Boriack-Sjodin PA; Infection Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA., Martinez-Botella G; Infection Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA., Carcanague D; Infection Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA., Eyermann CJ; Infection Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA., Gowravaram M; Infection Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA., Harang J; Infection Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA., Hale MR; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA., Ioannidis G; Infection Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA., Jahic H; Infection Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA., Johnstone M; Infection Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA., Kutschke A; Infection Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA., Laganas VA; Infection Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA., Loch JT 3rd; Infection Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA., Miller MD; Infection Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA., Oguto H; Infection Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA., Patel SJ; Discovery Sciences, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA.
Publikováno v:
Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2015 Nov 15; Vol. 25 (22), pp. 5172-7. Date of Electronic Publication: 2015 Oct 14.
Autor:
Murphy-Benenato KE; Infection Innovative Medicines, AstraZeneca R&D Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Dangel B; Infection Innovative Medicines, AstraZeneca R&D Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Davis HE; Infection Innovative Medicines, AstraZeneca R&D Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Durand-Réville TF; Infection Innovative Medicines, AstraZeneca R&D Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Ferguson AD; Structure and Biophysics, and Reagents & Assay Development, Discovery Sciences, AstraZeneca R&D Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Gao N; Structure and Biophysics, and Reagents & Assay Development, Discovery Sciences, AstraZeneca R&D Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Jahić H; Infection Innovative Medicines, AstraZeneca R&D Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Mueller JP; Infection Innovative Medicines, AstraZeneca R&D Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Manyak EL; Structure and Biophysics, and Reagents & Assay Development, Discovery Sciences, AstraZeneca R&D Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Quiroga O; Infection Innovative Medicines, AstraZeneca R&D Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Rooney M; Infection Innovative Medicines, AstraZeneca R&D Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Sha L; Infection Innovative Medicines, AstraZeneca R&D Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Sylvester M; Infection Innovative Medicines, AstraZeneca R&D Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Wu F; Infection Innovative Medicines, AstraZeneca R&D Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Zambrowski M; Infection Innovative Medicines, AstraZeneca R&D Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Zhao SX; Infection Innovative Medicines, AstraZeneca R&D Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.
Publikováno v:
ACS medicinal chemistry letters [ACS Med Chem Lett] 2015 Mar 22; Vol. 6 (5), pp. 537-42. Date of Electronic Publication: 2015 Mar 22 (Print Publication: 2015).
Autor:
Murphy-Benenato KE; Infection Innovative Medicines and ‡Discovery Sciences, AstraZeneca R&D Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Bhagunde PR, Chen A, Davis HE, Durand-Réville TF, Ehmann DE, Galullo V, Harris JJ, Hatoum-Mokdad H, Jahić H, Kim A, Manjunatha MR, Manyak EL, Mueller J, Patey S, Quiroga O, Rooney M, Sha L, Shapiro AB, Sylvester M, Tan B, Tsai AS, Uria-Nickelsen M, Wu Y, Zambrowski M, Zhao SX
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2015 Mar 12; Vol. 58 (5), pp. 2195-205. Date of Electronic Publication: 2015 Mar 03.
Autor:
Murphy-Benenato KE; Department of Chemistry, Infection Innovative Medicines, and Discovery Sciences, AstraZeneca R&D, Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Olivier N; Department of Chemistry, Infection Innovative Medicines, and Discovery Sciences, AstraZeneca R&D, Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Choy A; Department of Chemistry, Infection Innovative Medicines, and Discovery Sciences, AstraZeneca R&D, Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Ross PL; Department of Chemistry, Infection Innovative Medicines, and Discovery Sciences, AstraZeneca R&D, Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Miller MD; Department of Chemistry, Infection Innovative Medicines, and Discovery Sciences, AstraZeneca R&D, Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Thresher J; Department of Chemistry, Infection Innovative Medicines, and Discovery Sciences, AstraZeneca R&D, Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Gao N; Department of Chemistry, Infection Innovative Medicines, and Discovery Sciences, AstraZeneca R&D, Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Hale MR; Department of Chemistry, Infection Innovative Medicines, and Discovery Sciences, AstraZeneca R&D, Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.
Publikováno v:
ACS medicinal chemistry letters [ACS Med Chem Lett] 2014 Sep 23; Vol. 5 (11), pp. 1213-8. Date of Electronic Publication: 2014 Sep 23 (Print Publication: 2014).